Chai Discovery Raises $400 Million for AI-Designed Medicines
The molecular design startup reached a $3.8 billion valuation while expanding partnerships with major drugmakers.
Archive
The molecular design startup reached a $3.8 billion valuation while expanding partnerships with major drugmakers.
The Oakland company is expanding technology that structures fragmented patient information for clinical care, research and regulatory evidence.
The biotechnology company is advancing seven programs and plans to form focused affiliates as individual assets reach clinical milestones.